Brief: Ocuphire Says Diabetic Retinopathy Drug Did Not Meet Primary Endpoint

Opus Genetics

25/01/2023 22:07

Jan 25 (Reuters) - Ocuphire Pharma Inc  OCUP.O :
    * OCUPHIRE ANNOUNCES TOPLINE RESULTS FROM ZETA-1 PHASE 2
TRIAL OF
ORAL APX3330 IN DIABETIC RETINOPATHY AND PLANS FOR END-OF-PHASE
2 MEETING WITH FDA
    * OCUPHIRE PHARMA INC - ORAL APX3330 DEMONSTRATED FAVORABLE
SAFETY
AND TOLERABILITY
    * OCUPHIRE PHARMA INC - ORAL APX3330 DEMONSTRATED FAVORABLE
SAFETY
AND TOLERABILITY
    * OCUPHIRE PHARMA INC - ORAL APX3330 ACHIEVED STATISTICAL
SIGNIFICANCE ON A KEY PRE-SPECIFIED SECONDARY ENDPOINT
    * OCUPHIRE PHARMA INC - IN ZETA-1 PHASE 2 TRIAL, APX3330 DID
NOT
MEET PRIMARY ENDPOINT
    * OCUPHIRE PHARMA - ADDITIONAL EFFICACY ENDPOINTS
DIRECTIONALLY
FAVORABLE TO SUPPORT EFFECT OF APX3330 IN SLOWING PROGRESSION OF
DR, PRESERVING VISION
    * OCUPHIRE PHARMA INC - THERE WERE NO TREATMENT-RELATED
SERIOUS
ADVERSE EVENTS
    * OCUPHIRE PHARMA INC - TREATMENT-RELATED ADVERSE EVENTS
WERE
UNCOMMON, AND MOST WERE MILD IN SEVERITY
    * OCUPHIRE PHARMA INC - NO CHANGES WERE OBSERVED IN LIVER,
KIDNEY,
OR HEART FUNCTION AS WELL AS COMPLETE BLOOD COUNT AND
COMPREHENSIVE METABOLIC PANEL

Source text for Eikon:  ID:nGNX6mCxs1 
Further company coverage:  OCUP.O 
 ((Reuters.Briefs@thomsonreuters.com;))